Search Results Heading

MBRLSearchResults

mbrl.module.common.modules.added.book.to.shelf
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Are you sure you want to remove the book from the shelf?
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
    Done
    Filters
    Reset
  • Discipline
      Discipline
      Clear All
      Discipline
  • Is Peer Reviewed
      Is Peer Reviewed
      Clear All
      Is Peer Reviewed
  • Item Type
      Item Type
      Clear All
      Item Type
  • Subject
      Subject
      Clear All
      Subject
  • Year
      Year
      Clear All
      From:
      -
      To:
  • More Filters
      More Filters
      Clear All
      More Filters
      Source
    • Language
2,818 result(s) for "Webb, Tim"
Sort by:
A second-generation molecular clamp stabilised bivalent candidate vaccine for protection against diseases caused by respiratory syncytial virus and human metapneumovirus
Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are two medically important causes of respiratory tract infections and diseases. After more than five decades of research and development, vaccines have recently been approved for the prevention of lower respiratory tract disease caused by RSV. However, vaccines for hMPV remain in early-stage development. Here we describe the design and characterisation as well as pre-clinical development of a bivalent vaccine, VXB-241, comprised of the recombinantly expressed viral fusion proteins from both RSV and hMPV, stabilised in their pre-fusion conformation by combining the use of two technologies, the second-generation molecular clamp (MC2S) and key pre-fusion stabilizing mutations. Each of the two antigens were produced at high yield in a mammalian expression system and purified by an affinity capture resin specific to MC2S. Each antigen was demonstrated to adopt the pre-fusion conformation, which was stable for at least twelve months in liquid formulation at 2–8°C. Head-to-head evaluation in mouse immunogenicity studies showed that the VXB-241 candidate vaccine induced a neutralising immune response that was superior or equivalent to the pre-fusion stabilised comparator antigens for either RSV or hMPV, including the RSVPreF3 antigen of the licensed RSV vaccine, Arexvy (GSK). The results presented here have supported progression of VXB-241 into a Phase 1 clinical trial which commenced enrolment in August 2024 (ClinicalTrials.gov ID NCT06556147).
The Defender’s Dilemma
Cybersecurity is a constant, and, by all accounts growing, challenge. This report, the second in a multiphase study on the future of cybersecurity, reveals perspectives and perceptions from chief information security officers; examines the development of network defense measures—and the countermeasures that attackers create to subvert those measures; and explores the role of software vulnerabilities and inherent weaknesses.
Frank Ewart Webb
After D-Day, as a clinical student, he manned a field hospital near Wolverhampton that received incoming wounded soldiers from the beaches of Normandy, who were sent by rail from southern coastal ports.
Improving Software
Software vulnerabilities are what allow hackers to induce systems to behave in ways that their designers never intended and their users hardly expect. Even though software vendors might aspire to having secure software (assuming it does not prevent getting their product to market), vulnerabilities have not yet disappeared and will likely continue to characterize new software products. Their persistence and recurrence arises from the increasing complexity of software (NRC, 2009; Anderson and Hundley, 1998) coupled with the growing awareness of the money to be made by exploiting systems. This is exacerbated by the proliferation of devices connected and made available